Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 baricitinib + topical corticosteroids in moderate-to-severe atopic dermatitis with cyclosporine failure/intolerance
jRCT2080223904Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2018
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of baricitinib in atopic dermatitis (AD) (4 arms), sponsored by Eli Lilly and Company. Started May 2018; status: recruiting.
02
Drugs
baricitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2080223904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223904.